Zymeworks (ZYME) is undergoing a significant transformation into an oncology royalty platform, backed by a strong internal discovery engine and a favorable risk-reward profile compared to traditional biotech companies. The company currently holds over $400 million in liquid assets and has a $440 million milestone pipeline, ensuring operational support beyond 2028. A key highlight is the anticipated FDA Priority Review for zanidatamab, targeting first-line HER2-positive gastroesophageal adenocarcinoma (GEA), with a PDUFA date set for August 25, 2026. This approval could unlock $265 million in near-term milestone payments and establish substantial royalty streams. Additionally, Zymeworks is initiating a $125 million share repurchase program to further strengthen its financial position. The company’s valuation is characterized by a discounted forward price-to-earnings ratio and a justified premium on enterprise value to sales, although potential risks remain, including regulatory outcomes and uncertainties related to its early-stage pipeline.